PL3334760T3 - Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation - Google Patents

Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Info

Publication number
PL3334760T3
PL3334760T3 PL16760548T PL16760548T PL3334760T3 PL 3334760 T3 PL3334760 T3 PL 3334760T3 PL 16760548 T PL16760548 T PL 16760548T PL 16760548 T PL16760548 T PL 16760548T PL 3334760 T3 PL3334760 T3 PL 3334760T3
Authority
PL
Poland
Prior art keywords
antibody
capped
uncapped
cysteines
drug conjugation
Prior art date
Application number
PL16760548T
Other languages
Polish (pl)
Inventor
Xiaotian Zhong
Amarnauth Shastrie Prashad
Ronald William Kriz
Tao He
Will SOMERS
Wenge Wang
Leo Joseph LETENDRE
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3334760T3 publication Critical patent/PL3334760T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16760548T 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation PL3334760T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562204005P 2015-08-12 2015-08-12
PCT/IB2016/054789 WO2017025897A2 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
EP16760548.4A EP3334760B1 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Publications (1)

Publication Number Publication Date
PL3334760T3 true PL3334760T3 (en) 2021-10-11

Family

ID=56855760

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16760548T PL3334760T3 (en) 2015-08-12 2016-08-09 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Country Status (18)

Country Link
US (2) US10653794B2 (en)
EP (2) EP3808768A1 (en)
JP (2) JP6865209B2 (en)
KR (2) KR102146617B1 (en)
CN (1) CN107849121B (en)
AU (1) AU2016305331B2 (en)
CA (1) CA2938333A1 (en)
DK (1) DK3334760T3 (en)
ES (1) ES2864842T3 (en)
HR (1) HRP20210579T1 (en)
HU (1) HUE053956T2 (en)
IL (1) IL257420B (en)
MX (1) MX383558B (en)
PL (1) PL3334760T3 (en)
PT (1) PT3334760T (en)
RU (2) RU2021101009A (en)
SI (1) SI3334760T1 (en)
WO (1) WO2017025897A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257420B (en) * 2015-08-12 2022-08-01 Pfizer Antibodies that contain cysteine or cysteine containing a protective group and their use for the preparation of antibody and drug preparations
MX2019009372A (en) 2017-02-08 2019-12-11 Pfizer Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation.
MA68842B1 (en) * 2017-08-04 2025-01-31 Amgen Inc. CYS-MABS CONJUGATION PROCESS
CN113195487A (en) * 2018-10-12 2021-07-30 杭州多禧生物科技有限公司 2,3-Diaminosuccinyl conjugate linker
US11478553B2 (en) 2019-02-15 2022-10-25 Wuxi Biologies Ireland Limited Process for preparing antibody-drug conjugates with improved homogeneity
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
TW202102270A (en) * 2019-03-21 2021-01-16 美商伊繆諾金公司 Methods of preparing cell-binding agent-drug conjugates
JP2023554489A (en) * 2020-12-22 2023-12-27 ノバルティス アーゲー Method for reducing oxidation levels of cysteine residues in secreted recombinantly expressed proteins in cell culture
WO2023067626A1 (en) * 2021-10-20 2023-04-27 Dr. Reddy's Laboratories Limited A cell culture process to produce an antibody composition
AU2024325277A1 (en) * 2023-08-11 2026-01-29 Amgen Inc. Methods of solid phase antibody conjugation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
EP0604580A1 (en) * 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
ATE526401T1 (en) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc METHOD FOR PRODUCING PROTEINS WITH FREE CYSTEINE RESIDUE
WO2003048357A1 (en) * 2001-12-04 2003-06-12 Mitsubishi Pharma Corporation Method of activating protein
JP5335422B2 (en) * 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
KR20090016727A (en) * 2006-05-26 2009-02-17 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Methods for site-specific pegylation
MX354993B (en) * 2007-07-09 2018-03-28 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides.
BRPI0907046A2 (en) * 2008-01-18 2015-07-28 Medimmune Llc Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
US20100035253A1 (en) * 2008-03-19 2010-02-11 Intelligent Bio-Systems, Inc. Methods And Compositions For Incorporating Nucleotides
SG176947A1 (en) 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
US9005926B2 (en) * 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
MX2012006406A (en) * 2009-12-04 2012-07-25 Genentech Inc Multispecific antibodies, antibody analogs, compositions, and methods.
MX336540B (en) * 2010-06-08 2016-01-22 Genentech Inc Cysteine engineered antibodies and conjugates.
RU2018119112A (en) 2011-05-27 2018-11-07 Эббви Байотекнолоджи Лтд. COMPOSITIONS AND METHODS BASED ON DAC HYP
BR112014020697B1 (en) * 2012-02-24 2024-01-09 Alteogen Inc MODIFIED ANTIBODY COMPRISING A MOTIF CONTAINING CYSTEINE AT THE TERMINATION OF THE ANTIBODY, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING A DRUG LINKED TO THE MODIFIED ANTIBODY AND METHOD OF PRODUCING THE SAME
US9018172B2 (en) 2012-09-26 2015-04-28 Massachusetts Institute Of Technology Modification of peptides via SNAr reactions of thiols with fluorinated aromatics
WO2015065954A1 (en) * 2013-11-04 2015-05-07 Pfizer, Inc. Anti-efna4 antibody-drug conjugates
EP3077522A1 (en) * 2013-12-04 2016-10-12 Immunogen, Inc. Compositions and methods for antibody production
KR101871088B1 (en) 2014-01-27 2018-06-25 화이자 인코포레이티드 Bifunctional cytotoxic agents
BR112017018706B1 (en) 2015-03-20 2023-01-24 Pfizer Inc BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE PHARMACOPHERE CTI, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL257420B (en) * 2015-08-12 2022-08-01 Pfizer Antibodies that contain cysteine or cysteine containing a protective group and their use for the preparation of antibody and drug preparations

Also Published As

Publication number Publication date
RU2018105128A (en) 2019-09-12
KR102146617B1 (en) 2020-08-20
RU2018105128A3 (en) 2020-07-27
MX383558B (en) 2025-03-14
WO2017025897A3 (en) 2017-04-06
KR20180038041A (en) 2018-04-13
KR20200100850A (en) 2020-08-26
HUE053956T2 (en) 2021-08-30
US10653794B2 (en) 2020-05-19
RU2021101009A (en) 2021-02-20
IL257420A (en) 2018-06-28
IL257420B (en) 2022-08-01
CN107849121B (en) 2021-11-09
ES2864842T3 (en) 2021-10-14
WO2017025897A2 (en) 2017-02-16
BR112018001904A2 (en) 2018-09-18
CA2938333A1 (en) 2017-02-12
US11980669B2 (en) 2024-05-14
US20190030183A1 (en) 2019-01-31
EP3334760A2 (en) 2018-06-20
HRP20210579T1 (en) 2021-05-28
AU2016305331B2 (en) 2019-05-16
MX2018001686A (en) 2019-01-31
DK3334760T3 (en) 2021-04-19
JP2018525990A (en) 2018-09-13
SI3334760T1 (en) 2021-07-30
CN107849121A (en) 2018-03-27
JP6865209B2 (en) 2021-04-28
PT3334760T (en) 2021-04-23
KR102319622B1 (en) 2021-11-02
JP2021118694A (en) 2021-08-12
RU2742260C2 (en) 2021-02-04
HK1252799A1 (en) 2019-06-06
US20200230256A1 (en) 2020-07-23
EP3808768A1 (en) 2021-04-21
EP3334760B1 (en) 2021-03-10
AU2016305331A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
IL257420A (en) Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
IL278891A (en) Anti-her2 antibody-drug conjugates, compositions comprising same and uses thereof
IL267323A (en) Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
PL3378859T3 (en) Benzofuran derivative, preparation method thereof and use thereof in medicine
HUE053332T2 (en) Anti-cMet antibody-drug conjugates and methods for their use
SG11201606898TA (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
SI3347379T1 (en) ANTI-TIGIT antibodies, ANTI-PVRIG antibodies and combinations thereof
HUE054037T2 (en) Activable antibody-active conjugates against CD71 and methods for their use
IL247659A0 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
GB201717966D0 (en) Immunotoxins, formulations thereof and their use in medicine
IL256726A (en) Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
SI3265123T1 (en) Antibodies, uses and procedures
GB201614162D0 (en) Antibodies, uses thereof and conjugates thereof
IL266112A (en) Anti-edb antibodies and antibody-drug conjugates
SI3544637T1 (en) Native omv-antigen conjugates and use thereof
IL249453A0 (en) Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
ZA201908091B (en) Indole-formamide derivative, preparation method therefor and use thereof in medicine
IL264009A (en) Antibodies with low immunogenicity and uses thereof
ZA201706254B (en) Oil blends, processes for the preparation thereof and their use in formulas
GB201419108D0 (en) Materials and methods relating to linkers for use in antibody drug conjugates
FI20165821L (en) Method of measuring physical quantities, and measuring arrangement used in the method
IL237283A0 (en) Dldh, derivatives thereof and formulations comprising same for use in medicine
GB2536266B (en) Improvements in and relating to post drivers.
GB2513859B (en) Agrochemical composition, method for its preparation and the use thereof